Spexis receives approval of an extension of the deadline for the publication
of its 2023 annual report and audited financials until latest May 31, 2024.

Spexis AG / Key word(s): Miscellaneous
Spexis receives approval of an extension of the deadline for the publication
of its 2023 annual report and audited financials until latest May 31, 2024.

30-Apr-2024 / 20:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, April 30, 2024

Spexis receives approval of an extension of the deadline for the publication
of its 2023 annual report and audited financials until latest May 31, 2024.

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on
macrocycle therapeutics for rare diseases and oncology, today announced that
the company has been granted an extension to publish its 2023 annual report
from SIX Exchange Regulation AG ("SIX"), with said publication to occur no
later than 31 May 2024.

Paragraph I of the SIX decision dated April 29, 2024 reads as follows:

I. The exemption request of Spexis (Issuer) dated 29 April 2024 regarding an
extension of the deadline to publish its 2023 annual report and to file such
report with SIX Exchange Regulation AG until 31 May 2024 at the latest is
granted with the following reservation (lit.a) and under the following
conditions (lit. b):

a. SIX Exchange Regulation AG reserves the right to suspend trading of the
registered shares of the Issuer in case its 2023 annual report is not
published in accordance with the provisions on ad hoc publicity (Art. 53 of
the Listing Rules (LR) in connection with the Directive on Ad hoc Publicity
(DAH)) and not filed with SIX Exchange Regulation AG until Friday, 31 May
2024, 11.59 pm CET, at the latest.

b. Spexis is required to publish a notice in accordance with the provisions
on ad hoc publicity (Art. 53 LR in connection with the DAH) concerning this
decision until Tuesday, 30 April 2024, 11.59 pm CET, at the latest. The
notice must contain:

  * the unaltered reproduction of the wording of para. I. of this decision,
    placed in a prominent position;

  * the reasons for the application of the Issuer requesting an extension of
    the deadline to publish its 2023 annual report and to file such report
    with SIX Exchange Regulation AG.

The reason for the delay in publishing the 2023 annual report relate to i)
the ongoing discussions with legal counsel and our moratorium administrator
regarding the treatment of assets subject to enforcement actions undertaken
by Spexis' major creditor (SPRIM Global Investments, as announced on
November 29, 2023, and which we allege are wrongful) and ii) ongoing, good
faith negotiations with SPRIM towards a mutually acceptable resolution of
said dispute. Accordingly, the audit costs have not been approved at this
stage and a further extension may be required in respect to audited
accounts. The company firmly expects to publish unaudited financial
statements by the end of May 2024.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in
Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases
and oncology. For further information please visit: www.spexisbio.com.

For further information please contact:

      For Investors: Martin Jakobovic     For Media: Dr. Stephan Feldhaus
       Head of Finance & acting Chief       Feldhaus & Partner +41 79 865
   Financial Officer Spexis AG +41 61                                9256
    567 16 00 (1)IR@spexisbio.com  1.     (1)feldhaus@feldhaus-partner.ch
              mailto:IR@spexisbio.com                                  1.
                                         mailto:feldhaus@feldhaus-partner
                                                                      .ch

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Spexis AG
                   Hegenheimermattweg 125
                   4123 Allschwil
                   Switzerland
   Phone:          +41 61 567 1600
   Fax:            +41 61 567 1601
   E-mail:         info@spexisbio.com
   Internet:       www.spexisbio.com
   ISIN:           CH0106213793
   Valor:          SPEX
   Listed:         SIX Swiss Exchange
   EQS News ID:    1893495

End of Announcement EQS News Service
---------------------------------------------------------------------------

1893495 30-Apr-2024 CET/CEST